Kurse werden geladen...
Prognose
| Kaufen | 1 |
| Halten | 1 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Baudax Bio Announces Corporate Update
Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition» Mehr auf globenewswire.com
Baudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug Tag
FDA grants the Orphan Drug designation to Baudax (BXRX) for its lead pipeline candidate, TI-168, to treat Hemophilia A patients with inhibitors.» Mehr auf zacks.com
Why Is Baudax Bio (BXRX) Stock Up 75% Today?
As the market attempted to recover from a recent series of disappointing performances, biotechnology firm Baudax Bio (NASDAQ: BXRX ) represented a dramatic winner. Earlier Thursday morning, management disclosed that the U.S. Food and Drug Administration (FDA) granted its lead clinical candidate orphan drug designation.» Mehr auf investorplace.com
Unternehmenszahlen
| (EUR) | 2022 | |
|---|---|---|
| Umsatz | 1,18 Mio | 24,56% |
| Bruttoeinkommen | −5,35 Mio | 345,79% |
| Nettoeinkommen | −54,81 Mio | 215,29% |
| EBITDA | −33,17 Mio | 21,85% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 0,00€ |
52 Wochen-Hoch/Tief | 3,07€ - 0,0121€ |
| Dividenden | Nein |
Beta | 1,58 |
KGV (PE Ratio) | - |
KGWV (PEG Ratio) | - |
KBV (PB Ratio) | - |
KUV (PS Ratio) | - |
Unternehmensprofil
| Name | BAUDAX BIO INC.(WI)DL-,01 |
| CEO | Dr. Geraldine A. Henwood Ph.D. |
| Sitz | Malvern, pa USA |
| Mitarbeiter | 9 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | BXRX |
Assets entdecken
Shareholder von BAUDAX BIO INC.(WI)DL-,01 investieren auch in folgende Assets
